Sarcoma
M. Voermans, M. Bui, MD, PhD, E. Conrad, G. D'Amato, MD, J. Goodwin, A. O'Driscoll, MBA, MPA, R. Ratan, MD, MEd, D. Reinke, MS, NP, MBA, E. Peregrine Antalis, MPH, PhD
September 2021 Vol 12, No 9 | September 16, 2021
The authors propose potential solutions to the challenges faced by patients with Epithelioid Sarcoma.
May 2020 Vol 11, No 5 | May 7, 2020
Although not the most common of
cancers, pediatric and adult sarcomas
affect a significant proportion
of patients, and managing these malignancies
first requires understanding
them, according to Paula Sanborn, BSN,
RN.
Web Exclusives | December 11, 2019
On December 3, 2019, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to the biopharmaceutical company Adaptimmune Therapeutics for ADP-A2M4 for the treatment of synovial sarcoma. Earlier this year, the FDA granted Orphan Drug designation to the agent for the treatment of soft tissue sarcomas.
Results 1 - 3 of 3
